Back to Acceleration Radar
ITGRInteger Holdings Corp
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · Mid
$126.54−0.02%
As of 23 Oct 2026Mkt cap $4.3B
Stage 13
WAIT
Fundamentals
43.4/75
Technical
3.8/15
Independent
47.2/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +0.3%
- 3M
- +27.3%
- 6M
- +47.1%
- 1Y
- +16.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 34.6xHist median 38.5x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 40.2x
- FCF yield
- 2.5%
Quality
- ROIC
- 6.6%
- Operating margin
- 11.9%
- FCF margin
- 5.7%
- Current ratio
- 3.3x
Growth
- Revenue growth
- +8.0%Latest FY YoY
- Revenue CAGR
- +11.0%
- EPS CAGR
- −0.2%
- FCF CAGR
- +0.5%
Capital
- Share-count trend
- +2.7%3Y annualised
- Net debt
- $1.2B6.1x OCF
Annual trend
- CAGR 2021–2025
- +11.0%
- Latest · 2025
- $2B
- YoY
- +8.0%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded